At the current moment research has shown that in the development of the disorder the main part plays the immune system, so the disease may be called autoimmune by nature. Usually psoriasis causes formation of dry, red, inflamed marks on the skin. However in some cases, patients suffering from psoriasis do not express any signs of the disease on the skin. These skin marks are called psoriatic plaques. Such plaques are areas of chronic inflammation and increased proliferation lymphocytes, macrophages and keratinocytes of the skin as well as increased angiogenesis in the subcutaneous layer, thus the skin thickens at the affected areas. Psoriatic plaques are usually formed at the areas of the skin which are exposed to increased friction and pressure - elbows, knees and buttocks, however in some patients the plaques may appear on other parts of the body.

A large number of techniques and treatments exist for the management of psoriasis amongst them - anti-inflammatory therapy with Dermovate which is used in treatment of non-plaque psoriasis, and other conditions such as excema, lichen multiforme, lupus erythematosus, and etc.

The preparation is a glucocorticoid, which is intended for external use. The drug expresses anti-inflammatory and antiallergic effects, removes swelling, hyperemia and itching at the place of application. The preparation is intended for external use only and should not be applied to mucous surfaces. In local use, especially in cases when the place of application is covered by an occlusive bandage or is bruised, systemic absorption of the drug is possible, which may lead to development of systemic side-effects. The active ingredient of the drug Clobetasole propionate does not bind to blood proteins at the same rate as hydrocortisone, but has a longer half-life time. The drug is metabolized via the liver and partially via the kidneys. The drug is excreted with urine.

Dermovate is applied to the affected areas of the skin once or twice a day for the period prescribed by the health provider. In cases of severe hyperkeratosis, the anti-inflammatory effect of the drug may be potentiated with the use of occlusive bandage. Priorly to the application the skin should be cleansed thoroughly. If no clinical effect is monitored within 2 to 4 weeks after beginning of Dermovate application, then an additional consultation with the health care provider is necessary. The drug is recommended for short-term therapy.

The preparation is considered to be highly efficient and should not be used consecutively for a long time. Consult the health care provider for additional information on the drug.